Precision Medicine Group

We’re excited to welcome Mohammad Zahid as Precision Medicine Group’s new Senior Vice President Global IT Operations! Mohammad brings extensive experience as a visionary IT executive leading Global IT Operations and strategy for private and public organizations. He has been a change agent for large scale Technology transformations to include M & A and Divestitures in his last 2 roles. Most recently, as Vice President – Head of Global Infrastructure & Support at Aramark Uniform Services, now Vestis (NYSE: VSTS), he oversaw IT operations for a $2.8B business with 350+ locations and 20,000+ employees. He successfully built an independent infrastructure and support services organization post-divestiture, driving scalability, security, and operational excellence across critical systems. Prior to Vestis, Mohammad held senior leadership roles at Motrex LLC (formerly Exide Technologies), where he managed complex divestitures and launched new companies, and served as Chief Technology Officer for an IT managed services provider. His career reflects a consistent focus on strategic execution, workforce optimization, and delivering exceptional technology solutions. Welcome to Precision, Mohammad!

New whitepaper: Moving ADCs to the Front Line: Perspectives from FDA Oncology Experts Moving ADCs into a frontline setting is a true measure of success and can lead to a potential blockbuster asset. Harpreet Singh, MD and Nicholas Richardson, DO, MPH have combined their insights from their time in the FDA and beyond, into a whitepaper that includes: -Case studies on successfully moving ADCs into frontline settings -Keys to gaining accelerated approval based on single-arm studies -The importance of early studies in managing toxicities Watch the preview video with Harpreet, then visit instituteatprecision.com to download the whitepaper.

What's next for biotech after JPM 2026? Tomorrow, join Endpoints News and leaders from Precision For Medicine and Precision AQ for a forward-looking discussion on the trends reshaping drug development and commercialization. Our Chief Medical Officer, Harpreet Singh, MD shares a quick preview below. November 12 | 2:30 PM ET https://hubs.ly/Q03S5Nvy0

This Veterans Day, Precision salutes all the brave men and women of our military, past and present. We offer special gratitude to our very own blanca mendez, Cameron Stewart, and Dan Forero, featured in this video. Watch them discuss their service, then take a moment to personally thank a veteran for the sacrifices they have made to ensure the freedoms we all enjoy.

We were proud to host a special event at SITC 2025 celebrating the launch of the Institute@Precision, a new collaborative forum for biopharma innovation. The Institute@Precision serves as a hub where scientists, physicians, regulators, commercial leaders, and global experts come together to tackle the most pressing challenges in biopharma. Each quarter, the Institute will spotlight focused topics shaping the industry featuring perspectives from across R&D and commercialization. It was an honor to mark this milestone alongside our colleagues at Marengo Therapeutics, true leaders in the space. https://lnkd.in/eRvSUyHZ #SITC2025 #OncologyInnovation #InstituteAtPrecision #ScientificExcellence Kevin Chin, Ke Liu , MD, PhD, Chad Clark, Harpreet Singh, MD, Precision For Medicine

The emergence of GLP-1RA therapy as a population-level intervention may require a fundamental rethinking of cancer care delivery, especially as new agents with different molecular structures, chemical properties, pharmacokinetic profiles, and intended effects come to market. In this article in The Cancer Letter researched and authored by Deb Phippard, PhD, Chief Scientific Officer, Precision for Medicine, she summarizes the recent data that suggests both the early opportunities and risks of GLP-1RA for oncology. “The intersection of GLP-1RA therapy and cancer care presents unique opportunities to apply and advance precision medicine. Tumor profiling in GLP-1RA users may reveal distinct molecular signatures that reflect the metabolic environment in which these cancers develop. The profound effects of GLP-1RA therapy on gut microbial composition create opportunities for microbiome-based biomarker development and therapeutic interventions. Yet, the widespread adoption of GLP-1RA therapy presents challenges for clinical trial design. The metabolic and physiological changes induced by GLP-1RAs represent potential confounding variables that could significantly influence trial outcomes. Current clinical trials rarely account for concurrent GLP-1RA use, despite some estimates showing that more than 10% of Americans have used them at some point, creating potential bias in efficacy and safety assessments. Patients on GLP-1RA therapy may respond differently to investigational cancer treatments, and these differences could mask true treatment effects or create apparent benefits that do not generalize to the broader population.” Subscription required to read article: https://lnkd.in/eJin2ERK?

Mechanism-driven innovation is shaping the next chapter of ADC development! In this discussion from ESMO 2025, our Chief Medical Officer Harpreet Singh, MD speaks with Cesar Perez M.D., Director of the Drug Development Unit at the Sarah Cannon Research Institute at Florida Cancer Specialists & Research Institute, about early Phase 1/2 data on CRB-701, a next-generation Nectin-4–targeting ADC. Designed to reduce toxicities seen with MMAE-based ADCs, CRB-701 demonstrated promising response rates, durable disease control, and a manageable safety profile across tumor types, including head and neck and cervical cancers. Watch their discussion here. Corbus Pharmaceuticals

From JPM insights to precision medicine’s role in market access, discover how biotech leaders are tackling the toughest challenges: bridging science with commercial viability and building investor confidence. Join Precision For Medicine and Precision AQ for a discussion on what success looks like in today’s biotech climate, and how strategic partnerships can make it happen. Nov 12 | 2:30 PM ET Register today: https://bit.ly/4qq2Bnr Featuring: Harpreet Singh, MD, Deb Phippard Greg Gregory, PhD, Daniel Cummings, Hannah Deresiewicz

Precision for Medicine is heading to SITC 2025, and we’re bringing the expertise to spark new collaborations in cancer research. Stop by Booth 302 to explore how our integrated clinical and translational strategies are helping move promising therapies forward. Whether you're focused on operational innovation, biomarker-driven insights, or tailored immunotherapy development. We’re ready to connect!

Today, Precision introduces a new collaborative forum for biopharma innovation, the Institute@Precision! https://lnkd.in/eNGBjWHu The Institute@Precision is a hub of expertise where Precision scientists, physicians, regulators, commercial leaders, clients and global experts convene to address the most pressing challenges in biopharma. Each quarter, Precision will engage global thought leaders on focused topics impacting the industry. The first content release is now available and offers an array of R&D and commercial perspectives on antibody drug conjugates (ADCs). It’s been 25 years since the first ADC approval, with 15 now approved and today, more than 200 being evaluated in clinical trials. We’re excited to share our experience with ADC programs with the industry to help catalyze innovation. Margaret Keegan, our Chief Executive Officer states, “With the Institute@Precision, we are harnessing the power of our knowledge to support the broader industry. We look forward to engaging with the life sciences community as we address critical topics where our unique molecule to market perspectives can turn knowledge into progress and insight into impact.” Be a part of the conversation, visit https://lnkd.in/eNGBjWHu